ANAB
ANAPTYSBIO, INCCompany Information
- Company Name
- ANAPTYSBIO, INC
- CIK
- CIK0001370053
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ANAB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ANAB
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-02
- Last sale
- 2026-03-30
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 217,530
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 30,180,999
- Shares outstanding
- 28,691,000
- Ownership
- 105.19%
Earnings Market Reaction
- Filing date
- 2026-05-12
- Price on filing date
- —
- 1-month reaction
- -23.19%
- 3-month reaction
- -18.63%
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 248 | 238 | 110 | 44 | 99 | 123 | 192 | 72 | 54 | 36 | 26 | 35 | ||||||
| Receivables Net Current | 26 | 34 | 76 | 21 | 18 | 41 | 12 | 9 | 7 | 7 | 3 | 3 | ||||||
| Available For Sale Securities Debt Securities Current | 38 | 73 | 139 | 221 | 241 | 262 | 239 | 279 | 301 | 355 | 387 | 394 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 5 | 6 | 5 | 5 | 6 | 6 | 8 | 11 | 9 | 12 | 6 | ||||||
| Assets Current | 316 | 350 | 331 | 292 | 363 | 432 | 449 | 367 | 372 | 407 | 428 | 439 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 12 | 13 | 13 | 13 | 14 | 14 | 15 | 15 | 16 | 16 | 17 | 17 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | 0 | 8 | 28 | 43 | 35 | 28 | 43 | 15 | 27 | 40 | 59 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 330 | 364 | 353 | 335 | 422 | 484 | 493 | 427 | 406 | 452 | 487 | 517 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 8 | 4 | 3 | 3 | 6 | 4 | 4 | 5 | 5 | 5 | 7 | 5 | ||||||
| Accrued Liabilities Current | 32 | 33 | 33 | 30 | 36 | 40 | 38 | 34 | 26 | 31 | 31 | 35 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 42 | 39 | 38 | 36 | 44 | 45 | 44 | 40 | 32 | 37 | 39 | 42 | ||||||
| Operating Lease Liability Noncurrent | 11 | 12 | 13 | 13 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 17 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 838 | 810 | 793 | 793 | 832 | 830 | 821 | 715 | 706 | 703 | 695 | 687 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | -0 | 0 | 0 | 1 | -0 | -1 | -1 | -2 | -4 | ||||||
| Retained Earnings Accumulated Deficit | -825 | -773 | -822 | -837 | -799 | -759 | -738 | -705 | -658 | -614 | -572 | -535 | ||||||
| Stockholders Equity | 13 | 37 | -29 | -45 | 34 | 71 | 84 | 10 | 48 | 88 | 120 | 148 | ||||||
| Liabilities And Stockholders Equity | 330 | 364 | 353 | 335 | 422 | 484 | 493 | 427 | 406 | 452 | 487 | 517 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 29 | 28 | 28 | 28 | 30 | 30 | 30 | 27 | 27 | 27 | 27 | 27 | ||||||
| Shares Outstanding | 29 | 28 | 28 | 28 | 30 | 30 | 30 | 27 | 27 | 27 | 27 | 27 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialANAPTYSBIO, INC (ANAB) — SEC Financial Statements & Analysis
ANAPTYSBIO, INC (ANAB) is a pharmaceutical preparations company, incorporated in DE. ANAPTYSBIO, INC trades on Nasdaq as: ANAB. ANAPTYSBIO, INC (ANAB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-12. Based on that filing, ANAPTYSBIO, INC carries a market cap of $1.06B, a P/E ratio of -39.60x, a P/B ratio of 83.22x, a P/S ratio of 4.56x, an enterprise value of $812.33M, and an EV/EBITDA multiple of 19.65x. On profitability, it posts an operating margin of 17.56%, a net margin of -11.53%, a Return on Equity (ROE) of -114.55%, a Return on Assets (ROA) of -7.13%, and a Return on Invested Capital (ROIC) of -135.05%. Per share, it reports EPS of $-0.93, diluted EPS of $-0.93, free cash flow per share of $0.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 107.73% year-over-year, net income growth of -80.95% year-over-year, and EPS growth of -79.65% year-over-year. On the balance sheet, it maintains a current ratio of 7.58x, a quick ratio of 7.49x, working capital of $274.41M, a debt-to-equity ratio of 3.27x, a debt ratio of 0.13, free cash flow of $4.41M (TTM), and net debt of $-248.47M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.06B
- P/E TTM
- -39.60x
- EPS TTM
- $-0.93
- P/B TTM
- 83.22x
- ROE TTM
- -114.55%
- ROA TTM
- -7.13%
- Debt To Equity
- 3.27x
- Free Cash Flow TTM
- $4.41M
- Net Revenue TTM Growth 1Y
- 107.73%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ANAPTYSBIO, INC in?
ANAPTYSBIO, INC (ANAB) operates in the Pharmaceutical Preparations industry.
What exchange does ANAB trade on?
ANAPTYSBIO, INC (ANAB) trades on the Nasdaq.
Where is ANAPTYSBIO, INC incorporated?
ANAPTYSBIO, INC is incorporated in DE.
When was ANAPTYSBIO, INC (ANAB)'s most recent SEC filing?
ANAPTYSBIO, INC (ANAB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-12.
What is ANAB's market cap?
ANAPTYSBIO, INC (ANAB) has a market capitalization of $1.06B as of 2026-03-31.
What is ANAB's EPS (earnings per share)?
ANAPTYSBIO, INC (ANAB)'s trailing twelve month EPS is $-0.93 as of 2026-03-31.
What is ANAB's ROE (return on equity)?
ANAPTYSBIO, INC (ANAB)'s trailing twelve month Return on Equity (ROE) is -114.55% as of 2026-03-31.
What is ANAB's ROA (return on assets)?
ANAPTYSBIO, INC (ANAB)'s trailing twelve month Return on Assets (ROA) is -7.13% as of 2026-03-31.
What is ANAB's ROIC (return on invested capital)?
ANAPTYSBIO, INC (ANAB)'s trailing twelve month Return on Invested Capital (ROIC) is -135.05% as of 2023-12-31.
What is ANAB's EV/EBITDA?
ANAPTYSBIO, INC (ANAB)'s trailing twelve month EV/EBITDA is 19.65x as of 2026-03-31.